Carregant...
CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment
Despite the development of targeted therapies and novel inhibitors, cancer remains an undefeated disease. Resistance mechanisms arise quickly and alternative treatment options are urgently required, which may be partially met by drug combinations. Protein kinases as signaling switchboards are freque...
Guardat en:
| Publicat a: | Pharmaceuticals (Basel) |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7760252/ https://ncbi.nlm.nih.gov/pubmed/33255177 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph13120418 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|